Lu, S., Provencio, M., Lisberg, A., Mascarenhas, E., Tanizaki, J., Cheng, Y., Kim, H. R., Liu, Y., Feng, S., Zhang, L., Toms, L., Yang, J. C., Goldberg, S. B. (2025). TROPION-Lung14: A phase 3 study of osimertinib ± datopotamab deruxtecan (Dato-DXd) as first-line (1L) treatment for patients with EGFR -mutated locally advanced or metastatic (LA/M) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8647